EGFR
EGFR (epidermal growth factor receptor) inhibitors are compounds that block the signaling of EGFR, a receptor that is often overexpressed in various cancers and plays a critical role in angiogenesis. EGFR inhibitors are used to prevent tumor growth and metastasis by disrupting the pathways that promote blood vessel formation in tumors. These inhibitors are widely used in cancer research and therapy. At CymitQuimica, we offer a diverse selection of high-quality EGFR inhibitors to support your research in oncology and angiogenesis.
Found 594 products of "EGFR"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Icotinib Hydrochloride
CAS:Icotinib Hydrochloride, an oral EGFR inhibitor (BPI-2009H), may halt cancer growth by blocking EGFR signaling.Formula:C22H22ClN3O4Purity:99.89%Color and Shape:SolidMolecular weight:427.88EGFR-IN-67
CAS:EGFR-IN-67 (Compound 7d) is a potent inhibitor of EGFR with anticancer activity (IC 50 = 0.34 μM) [1].Formula:C18H17N3SColor and Shape:SolidMolecular weight:307.41EGFR/HER2-IN-12
CAS:EGFR/HER2-IN-12 (compound 14b) serves as a dual inhibitor targeting EGFR and HER2, demonstrating 81% and 51% inhibition respectively at a concentration of 10 μM. This compound exhibits minimal toxicity towards A431 and MDA-MB-361 cancer cells [1].Formula:C25H17ClN4O3SMolecular weight:488.95SPH5030
CAS:SPH5030 is an irreversible, selective inhibitor of HER2.Formula:C31H31FN8O3Color and Shape:SolidMolecular weight:582.63EGFR-IN-25
CAS:EGFR-IN-25, an efficacious EGFR inhibitor, demonstrates IC50 values of 9 nM for BaF3 cells (EGFR DEL19/T790M/C797S) and 60 nM for A431 cells (WT), respectively.Formula:C34H43N9O2Color and Shape:SolidMolecular weight:609.76MTX-531
CAS:MTX-531 is a selective inhibitor of EGFR and PI3K with IC50 of 14.7 nM and 1.1-233 nM (PI3Kα, PI3Kβ...), respectively. It also acts as a weak agonist of PPARγ, with an EC50 of 3.4 μM in 293H cells.Formula:C22H20ClN5O2SColor and Shape:SoildMolecular weight:453.94JBJ-09-063 hydrochloride
JBJ-09-063 hydrochloride: targeted EGFR inhibitor, effective for various mutations and TKI-resistant lung cancer models.Formula:C31H30ClFN4O3SColor and Shape:SolidMolecular weight:593.11Z118332870
CAS:Z118332870 is a potent inhibitor of EGFR and BRD4.Formula:C18H18FN3O3Color and Shape:SolidMolecular weight:343.35BPIQ-II (hydrochloride)
CAS:BPIQ-II, a selective EGFR inhibitor with an IC50 of 8 pM, targets ATP sites and halts EGF signals inside cells.Formula:C15H11BrClN5Color and Shape:SolidMolecular weight:376.64PF-6422899
CAS:PF-6422899 irreversibly inhibits EGFR kinase activity by binding covalently to active-site cysteine residues in the ATP binding pocket of EGFR.Formula:C20H14ClFN4O2Color and Shape:SolidMolecular weight:396.8MJ04
CAS:MJ04 is a selective inhibitor of Janus Kinase 3 (JAK3) with an IC50 of 2.03 nM. It hinders T cell differentiation and suppresses pro-inflammatory cytokines in macrophages induced by Lipopolysaccharides. In mice, MJ04 exhibits favorable pharmacokinetic properties and promotes hair growth in a DHT-induced alopecia model in athymic mice, without notable toxicity (LD50>2 g/kg).Formula:C20H16FN5Color and Shape:SolidMolecular weight:345.37PF-06672131
CAS:PF-06672131 is a selective EGFR kinase inhibitor.Formula:C23H21ClFN5O2Color and Shape:SolidMolecular weight:453.9PD 173955-Analog1
CAS:PD 173955-Analog1 is a potent c-Src inhibitor known to have activity against a variety of cancers including colon, lung, head and neck carcinoma.Formula:C21H14Cl2N4O3Color and Shape:SolidMolecular weight:441.27EGFR/HER2-IN-2
CAS:EGFR/HER2-IN-2 (Compound ZINC35560729) is a dual EGFR and HER2 inhibitor that acts on both EGFR (IC50: 5.02 μM) and HER2 (IC50: 0.83 μM).Formula:C26H23N5O3Color and Shape:SolidMolecular weight:453.49EAI001
CAS:EAI001 is a potent and selective mutant epidermal growth factor receptor (EGFR) variant inhibitor that inhibits EGFRL858R/T790M with an IC50 value of 24 nM.Formula:C19H15N3O2SPurity:99.94%Color and Shape:SolidMolecular weight:349.41RG 14467
CAS:RG 14467 is an antagonist of epidermal growth factor-urogastrone.Formula:C14H14N2O3Color and Shape:SolidMolecular weight:258.27RG 14921
CAS:RG 14921 is a pyridone analog of erbstatin, epidermal growth factor (EGF) receptor tyrosine kinase, and cAMP-dependent kinase.Formula:C11H9NO3Color and Shape:SolidMolecular weight:203.19UNC-CA359
CAS:UNC-CA359: potent EGFR inhibitor, IC50=18 nM, strong anti-tumor effect, promising for chordoma.Formula:C18H14ClN3O2Color and Shape:SolidMolecular weight:339.78AFN941
CAS:AFN941 is a staurosporine analog, acting as a Jak3-specific inhibitor.Formula:C28H30N4O3Color and Shape:SolidMolecular weight:470.56CAY10717
CAS:CAY10717 inhibits 34/104 kinases at 100 nM, targets EGFR/ABL/B-Raf mutations, kills various cancer cells, and blocks HUVEC growth.Formula:C29H25F3N6O3Color and Shape:SolidMolecular weight:562.54HKI-357 dimaleate
CAS:HKI-357 dimaleate is an irreversible dual inhibitor of EGFR and ERBB2. HKI-357 suppresses EGFR autophosphorylation (at Y1068), and AKT and MAPK phosphorylation.Formula:C39H37ClFN5O11Color and Shape:SolidMolecular weight:806.2EGFR/HER2-IN-9
CAS:EGFR/HER2-IN-9, a compound inhibiting both EGFR and HER2, demonstrates potency with IC50 values of 3.2 nM for EGFR, 14 nM for HER2, and 8.3 nM against the EGFRFormula:C25H25ClFN5O4Color and Shape:SolidMolecular weight:513.95EGFR T790M/L858R-IN-5
CAS:EGFR T790M/L858R-IN-5 (example 52) functions as a potent EGFR T790M/L858R inhibitor, demonstrating a 92.9% inhibition rate at a concentration of 0.05 μM [1].Formula:C28H31N9OMolecular weight:509.61EGFR/C797S-IN-1
CAS:EGFR/C797S-IN-1: Potent EGFR-C797S inhibitor, IC50 of 0.128 µM, dose-dependent p-EGFR suppression, anti-tumor properties.Formula:C28H30N4O3Color and Shape:SolidMolecular weight:470.56EGFR-IN-63
CAS:EGFR- IN-63 is an EGFR inhibitor with an IC50 value of 0.096 μM. EGFR- IN-63 exhibited anticancer effects on MCF-7 cells (IC50: 2.49 μM).Formula:C20H12BrN5SColor and Shape:SolidMolecular weight:434.31(E/Z)-CP-724714
CAS:(E/Z)-CP-724714, comprising racemic mixtures of (E)-CP-724714 and (Z)-CP-724714 isomers, is a potent, selective, and orally active inhibitor of ErbB2 (HER2)[1].Formula:C27H27N5O3Purity:98%Color and Shape:SolidMolecular weight:469.54Tarlox-TKI
CAS:Tarlox-TKI (Kinase inhibitor-1) is a pan-ErbB inhibitor, the active ingredient of Tarloxotinib, which has antitumor activity.Formula:C19H18BrClN6OPurity:97.03%Color and Shape:SolidMolecular weight:461.74BIBX 1382 Dihydrochloride
CAS:BIBX 1382 Dihydrochloride blocks Lassa/Ebola entry, aids in studying virus-host interactions, and hints at kinase targets for therapy.Formula:C18H21Cl3FN7Color and Shape:SolidMolecular weight:460.76EGFR-IN-69
CAS:EGFR-IN-69: Potent EGFR inhibitor for NSCLC research; IC50: 4.3-25.6 nM against various EGFR mutations.Formula:C31H37Cl2N7O3SColor and Shape:SolidMolecular weight:658.64EGFR-IN-54
CAS:EGFR-IN-54 (Compound 3c) is a potent inhibitor of EGFR (IC50: 1.623 μM) and is toxic to cancer cells.Formula:C17H14N4O4S3Color and Shape:SolidMolecular weight:434.51EGFR-IN-21
CAS:EGFR-IN-21, a potent EGFR inhibitor, exhibits an IC50 of 0.38 nM, demonstrating significant antitumor activity.Formula:C36H44BrN10O2PColor and Shape:SolidMolecular weight:759.68EGFR-IN-73
CAS:EGFR-IN-73 (Compound 3f) effectively inhibits the prevalent EGFR mutation, EGFR Del19, exhibiting an IC50 value of 119 nM [1].Formula:C19H17ClFN3O4Purity:98%Color and Shape:SolidMolecular weight:405.81Antiproliferative agent-34
CAS:Antiproliferative Agent-34 (Compound A14), a multitarget kinase inhibitor, demonstrates IC50 values of 177 nM for EGFR L858R/T790M and 1567 nM for EGFR WT.Formula:C27H27N7O5Purity:98%Color and Shape:SolidMolecular weight:529.55EGFR-IN-89
CAS:EGFR-IN-89 (compound 13k) is a fourth-generation inhibitor selectively targeting EGFR mutations, exhibiting potent activity with an IC50 of 10.1 nM againstFormula:C26H31FN8O2SPurity:98%Color and Shape:SolidMolecular weight:538.64NSC81111
CAS:NSC81111 shows anticaner effects which is a potent and orally active inhibitor of EGFR-TK (IC50 = 0.15 nM) [1].Formula:C19H16O4Color and Shape:SolidMolecular weight:308.33EGFR-IN-50
CAS:EGFR-IN-50, a potent EGFR blocker, hinders L858R mutation; GI50: 8 nM for TEL-EGFR-L858R, 6.03 μM for T790M-L858R; curbs cancer cell growth.Formula:C24H26BrN3O4S2Color and Shape:SolidMolecular weight:564.51EGFR-IN-16
CAS:<p>EGFR-IN-16 (AG473) is an inhibitor of EGFR in human A431 cells.</p>Formula:C16H11NO3Purity:98%Color and Shape:SolidMolecular weight:265.26(E/Z)-AG490
CAS:(E/Z)-AG490 is a racemic mix of (E)- and (Z)-isomers; it inhibits tyrosine kinase, EGFR, Stat-3, and JAK2/3.Formula:C17H14N2O3Color and Shape:SolidMolecular weight:294.3EGFR-IN-75
EGFR-IN-75 inhibits EGFR WT/T790M; IC50s: 0.28/5.02 μM. It has anticancer and antioxidant effects.Formula:C10H6N6S2Color and Shape:SolidMolecular weight:274.32CGP52411
CAS:<p>CGP52411 is an orally active, and ATP-competitive inhibitor of EGFR (IC50: 0.3 μM).</p>Formula:C20H15N3O2Purity:99.78%Color and Shape:SolidMolecular weight:329.35EGFR-IN-53
CAS:EGFR-IN-53 (Compound 7) is a potent inhibitor of EGFR (IC50 = 8.264 μM) that exhibits cytotoxic activity against cancer cell lines [1].Formula:C14H13N3O2SColor and Shape:SolidMolecular weight:287.34NSC114126
CAS:<p>NSC114126 is a potent, oral EGFR-TK inhibitor with strong antiproliferative effects, promising for cancer research.</p>Formula:C22H20O4Color and Shape:SolidMolecular weight:348.39EGFR-IN-28
CAS:EGFR-IN-28 is a potent EGFR inhibitor. EGFR-IN-28 has antitumor activity .Formula:C31H39BrN10O3SColor and Shape:SolidMolecular weight:711.68BAY 2476568
CAS:BAY 2476568 is a selective and potent EGFR inhibitor that acts on both wild-type EGFR (IC50 <0.2 nM) and mutant EGFR (IC50 <0.2 nM).Formula:C24H27FN4O4Color and Shape:SolidMolecular weight:454.49LDC0496
CAS:LDC0496: Potent EGFR/Her2 exon 20 inhibitor; selective for wild-type EGFR, kinase-specific.Formula:C32H35N5O3Color and Shape:SolidMolecular weight:537.65Lavendustin C6
CAS:Lavendustin C6 is a effective tyrosine kinase inhibitor.Formula:C20H25NO5Color and Shape:SolidMolecular weight:359.42PDZ1i
CAS:PDZ1i: potent MDA-9/Syntenin inhibitor; crosses blood-brain barrier; targets GBM, FAK, EGFRvIII; lowers MMP secretion.Formula:C28H26N8O4Color and Shape:SolidMolecular weight:538.56Nazartinib mesylate
CAS:Nazartinib mesylate is a novel, covalent mutant-selective inhibitor of EGFR (Ki and Kinact: 31 nM and 0.222/min on EGFR(L858R/790M) mutant).Formula:C27H35ClN6O5SPurity:98%Color and Shape:SolidMolecular weight:591.12DBPR112
CAS:DBPR112: oral furanopyrimidine EGFR inhibitor; IC50: 15 nM (EGFRWT), 48 nM (L858R/T790M); blocks ATP site, strong antitumor effects.Formula:C32H31N5O3Purity:99.25%Color and Shape:SolidMolecular weight:533.62Tyrphostin AG 112
CAS:Tyrphostin AG 112 is an inhibitor of EGFR phosphorylation.Formula:C13H8N4OPurity:99.14%Color and Shape:SolidMolecular weight:236.23Epertinib
CAS:<p>Epertinib is a reversible and selective tyrosine kinase inhibitor of EGFR, HER2, and HER4 (IC50s: 1.48 nM, 7.15 nM, and 2.49 nM).</p>Formula:C30H27ClFN5O3Purity:98%Color and Shape:SolidMolecular weight:560.02RTC-5
CAS:RTC-5 (TRC-382) is a phenothiazine compound that has been specifically enhanced for its potent anti-cancer properties.Formula:C24H22ClF3N2O3SPurity:98.14%Color and Shape:SolidMolecular weight:510.96SDZ281-977
CAS:SDZ 281-977 is a derivative of Lavendustin A which is the EGF receptor tyrosine kinase inhibitor.Formula:C18H20O5Purity:99.64%Color and Shape:SolidMolecular weight:316.35MS 39
CAS:MS 39, a selective EGFR depressant, degrades mutant receptors in lung cancer lines without affecting wild-type. Effective in vitro and in mice.Formula:C55H71ClFN9O7SColor and Shape:SolidMolecular weight:1056.72EGFR-IN-2
CAS:EGFR-IN-2 is a oral and mutation-selective EGFR inhibito,NSCLC, with high selectivity for resistant single and double mutant T790M.Formula:C26H33N9O3SPurity:98.52% - 99.79%Color and Shape:SolidMolecular weight:551.66Nimotuzumab
CAS:<p>Nimotuzumab is a humanized therapeutic monoclonal antibody against epidermal growth factor receptor EGFR).</p>Purity:95.00% - 98.5% (SDS-PAGE); 96.4% (SEC-HPLC)Color and Shape:LiquidGefitinib N-oxide
CAS:Gefitinib is an EGFR tyrosine kinase inhibitor, with IC50 of 2-37 nM in NR6wtEGFR cells. Gefitinib N-oxide is the N-oxide derivative of Gefitinib.Formula:C22H24ClFN4O4Purity:98%Color and Shape:SolidMolecular weight:462.9BKI-1369
CAS:BKI-1369 is a bumped kinase inhibitor. BKI-1369 increases hERG-inhibitory activity (IC50:1.52 μM).Formula:C23H27N7OColor and Shape:SolidMolecular weight:417.51EGFR-IN-68
CAS:EGFR-IN-68, an EGFR inhibitor, has an IC50 of 0.33 μM and shows significant anticancer effects.Formula:C24H22N2OColor and Shape:SolidMolecular weight:354.44JBJ-04-125-02
CAS:JBJ-04-125-02: Oral EGFR inhibitor, targets EGFRL858R/T790M with 0.26 nM IC50, halts cancer growth, anti-tumor.Formula:C29H26FN5O3SPurity:98%Color and Shape:SolidMolecular weight:543.61GW 583340 dihydrochloride
CAS:<p>GW 583340 dihydrochloride is a potent and orally available dual EGFR/ErbB2 inhibitor and inhibits 80% of tumor growth in a mouse xenograft mode.</p>Formula:C28H27Cl3FN5O3S2Purity:98.80%Color and Shape:SolidMolecular weight:671.03EGFR-IN-64
CAS:EGFR-IN-64 inhibits EGFR with 0.33 μM IC50, showing promising anticancer properties.Formula:C20H21N3O3Color and Shape:SolidMolecular weight:351.4JNJ28871063 hydrochloride
CAS:ErbB receptor family inhibitorFormula:C24H28Cl2N6O3Purity:98%Color and Shape:SolidMolecular weight:519.42Mutated EGFR-IN-3
CAS:Mutated EGFR-IN-3: ATP-competitive, selective dibenzodiazepinone inhibitor for EGFR mutations, IC50 12-13 nM.Formula:C31H29FN4O2Purity:98%Color and Shape:SolidMolecular weight:508.59Mutated EGFR-IN-2
CAS:Mutated EGFR-IN-2 is an inhibitor of mutant-selective EGFR.Formula:C29H35FN8O3Purity:98%Color and Shape:SolidMolecular weight:562.64Selatinib
CAS:<p>Selatinib is an orally active and potent dual inhibitor of EGFR and ErbB2 with anticancer activity that inhibits the growth of NCI-N87 tumor cells.</p>Formula:C29H26ClFN4O3SPurity:98.00%Color and Shape:SolidMolecular weight:565.06EGFR-IN-5
CAS:<p>EGFR-IN-5 inhibits EGFR & mutants; IC50: EGFR 10.4nM, L858R 1.1nM, L858R/T790M 34nM, L858R/T790M/C797S 7.2nM.</p>Formula:C31H38FN9OPurity:98.17%Color and Shape:SolidMolecular weight:571.69EGFR mutant-IN-2
CAS:EGFR mutant-IN-2 (Compound D51) is an inhibitor of EGFR mutants, specifically targeting EGFR L858R/T790M/C797S and EGFR del19/T790M/C797S mutants with IC50 values of 14 nM and 62 nM, respectively. This compound exhibits favorable pharmacokinetic (PK) parameters, safety properties, in vivo stability, and demonstrates antitumor activity [1].Formula:C27H27F3N6O2SColor and Shape:SolidMolecular weight:556.6EMI48
CAS:EMI48, a derivative of EMI1, exhibits increased efficacy against mutant EGFR compared to EMI1. It specifically inhibits EGFR triple mutants [1].Formula:C21H20N2O3Color and Shape:SolidMolecular weight:348.4EGFR-IN-39
CAS:EGFR-IN-39, an acrylamide, is a potent EGFR inhibitor and antitumor agent targeting NSCLC with low toxicity. See WO2021185348A1 for details.Formula:C24H25ClN6O3Color and Shape:SolidMolecular weight:480.95Tyrphostin 51
CAS:Tyrphostin 51 is an effective inhibitor of EGFR kinase.Formula:C13H8N4O3Purity:98%Color and Shape:SolidMolecular weight:268.23EMI56
CAS:EMI56, a derivative of EMI1, exhibits enhanced potency against mutant EGFR compared to EMI1. Additionally, EMI56 effectively inhibits EGFR triple mutants[1].Formula:C21H20N2O3Color and Shape:SolidMolecular weight:348.4MS 154N
CAS:<p>MS 154N is a negative control for MS 154, binds WT/L858R EGFR tightly (Kd 3-4.3nM), doesn't trigger mutant EGFR degradation.</p>Formula:C47H56ClFN8O8Color and Shape:SolidMolecular weight:915.45EGFR-IN-55
CAS:"EGFR-IN-55 targets EGFRWT (70 nM IC50) & EGFRL858R/T790M (3.9 nM IC50), halts NCI-H1975 cell cycle in G0/G1, showing anticancer properties."Formula:C25H25Cl2N7O2Color and Shape:SolidMolecular weight:526.42EGA
CAS:EGA blocks the entry of a variety of other acid-dependent bacterial toxins and viruses into mammalian cells and can be used to treat infectious diseases.Formula:C16H16BrN3OPurity:98% - 99.6%Color and Shape:SolidMolecular weight:346.22DS21360717
CAS:DS21360717 is an effective oral tyrosine kinase inhibitor with anticancer activity and IC50 of 0.49 nM.Formula:C21H23N7OPurity:98%Color and Shape:SolidMolecular weight:389.45EGFR-IN-49
CAS:EGFR-IN-49 selectively inhibits EGFR mutations T790M (IC50: 65 nM) & T790M/L858R (IC50: 13.6 nM), triggering apoptosis dose-dependently.Formula:C22H15N5O2SColor and Shape:SolidMolecular weight:413.45EGFR-IN-31
CAS:EGFR-IN-31: Potent EGFR inhibitor, targets mutations & overexpression in NSCLC; potential cancer research compound. (WO2021185298A1, 2)Formula:C32H36FN7O2Color and Shape:SolidMolecular weight:569.67Limertinib
CAS:<p>Limertinib (ASK120067) is a EGFR tyrosine kinase inhibitor targeting EGFR T790M, applicable for the study of non-small cell lung cancer.</p>Formula:C29H32ClN7O2Purity:97.44%Color and Shape:SolidMolecular weight:546.06EGFR/HER2-IN-3
CAS:EGFR/HER2-IN-3 (Compound ZINC21942954) is a dual EGFR and HER2 inhibitor.Formula:C26H23N5O3Color and Shape:SolidMolecular weight:453.49EphB1-IN-1
CAS:EphB1-IN-1 is a potent inhibitor of EphB1, exhibiting IC50 values of 3.0 nM for EphB1 G703C, 15 nM for EphB1 T697G, and 220 nM for EphB1 WT.Formula:C16H12Cl2N4O2Color and Shape:SolidMolecular weight:363.2Falnidamol
CAS:Falnidamol (BIBX 1382), an oral selective EGFR inhibitor, IC50 3 nM, weak on ErbB2 and others, anti-cancer pyrimido-pyrimidine.Formula:C18H19ClFN7Purity:98.816%Color and Shape:SolidMolecular weight:387.84A-935142
CAS:A-935142 enhances hERG (Kv 11.1) channels, slows inactivation, promotes activation, and shortens repolarization.Formula:C18H19F3N2O2Purity:98.97% - 99.91%Color and Shape:SolidMolecular weight:352.35Cloperastine fendizoate
CAS:Cloperastine fendizoate (Hustazol) inhibits the hERG K+ currents in a concentration-dependent manner (IC50: 27 nM).Formula:C40H38ClNO5Purity:99.97%Color and Shape:SolidMolecular weight:648.19PD 174265
CAS:PD 174265 is an effective, selective and reversible inhibitor of epidermal growth factor receptor (EGFR) with an IC50 of 0.45 nM.Formula:C17H15BrN4OPurity:99.51%Color and Shape:SolidMolecular weight:371.23Tyrphostin A25
CAS:Tyrphostin A25 (Tyrphostin AG 82) is a specific EGFR tyrosine kinase inhibitor and GPR35 agonist with an IC50 value of 0.94 μM for GPR35 and an EC50 value of 5.Formula:C10H6N2O3Purity:98.98%Color and Shape:Yellow Green Powder /Off-White SolidMolecular weight:202.17EGFR-IN-99
CAS:EGFR-IN-99 (JBJ-03-142-02) is an EGFR and HER2 Exon 20 insertion mutation inhibitor for the study of non-small cell lung cancer (NSCLC).Formula:C25H22FN7O3Purity:97.75%Color and Shape:SolidMolecular weight:487.49PKI-166
CAS:PKI-166: oral EGF-R tyrosine kinase inhibitor (IC50: 0.7 nM), halts growth & spread of many human cancers, including pancreatic.Formula:C20H18N4OPurity:99.2%Color and Shape:SolidMolecular weight:330.38EMI1
CAS:<p>EMI1 targets mutated EGFR in drug-resistant NSCLC research.</p>Formula:C20H18N2O3Purity:99.96%Color and Shape:SolidMolecular weight:334.37EGFR-IN-9
CAS:EGFR-IN-9 is a potent EGFR kinase inhibitor with IC50s of 7 nM, 28 nM for the wild type EGFR kinase and double mutant EGFR kinase (L858R/T790M).Formula:C29H24N4O3Purity:99.8%Color and Shape:SolidMolecular weight:476.53Rezivertinib
CAS:Rezivertinib (BPI-7711) is an EGFR inhibitor with antitumor activity and can be used to study central nervous system diseases.Formula:C27H30N6O3Purity:99.26% - 99.98%Color and Shape:SolidMolecular weight:486.57Epitinib succinate
CAS:Epitinib succinate (HMPL-813 succinate) is an orally active and brain penetration EGFR tyrosine kinase inhibitor and can be used in studies about cancer.Formula:C28H32N6O6Purity:98.02% - 99.79%Color and Shape:SolidMolecular weight:548.59LY 456236 hydrochloride
CAS:LY 456236 hydrochloride (MPMQ hydrochloride) is an mGlu1 receptor antagonist with an ic50 value of 143 nM.Formula:C16H16ClN3O2Purity:99.95%Color and Shape:SolidMolecular weight:317.77EGFR/CSC-IN-1
CAS:EGFR/CSC-IN-1 is a dual inhibitor targeting both the epidermal growth factor receptor (EGFR [IC50 10.52 nM]) and cancer stem cells (CSC), with potentialFormula:C54H54Cl2FN7O7S2Purity:98%Color and Shape:SolidMolecular weight:1067.08BMS-599626 Hydrochloride
CAS:BMS-599626 HCl (AC480 HCl) is an oral inhibitor of HER1, HER2, HER4 kinases, potentially blocking tumor growth. IC50: 22/32/190 nM.Formula:C27H28ClFN8O3Purity:99.98%Color and Shape:SolidMolecular weight:567.01JND3229
CAS:JND3229 inhibits EGFRC797S; IC50: 5.8-30.5 nM; halts cell growth; effective in non-small cell lung cancer study.Formula:C33H41ClN8O2Purity:98.75%Color and Shape:SolidMolecular weight:617.182′-Thioadenosine
CAS:2'-Thioadenosine (PD157432) serves as a selective and irreversible inhibitor of ErbB-1 and ErbB-2 tyrosine kinases, demonstrating an IC50 value of 45 µM againstFormula:C10H13N5O3SPurity:98%Color and Shape:SolidMolecular weight:283.31DZD1516
CAS:DZD1516, a potent and selective HER2 inhibitor (IC50 = 0.56 nM), demonstrates good blood-brain barrier permeability and exhibits antitumor activity in bothFormula:C28H27F2N7O3Purity:98%Color and Shape:SolidMolecular weight:547.56JGK-068S
CAS:Compound I (JGK-068S) is a potent inhibitor of the epidermal growth factor receptor (EGFR) [1].Formula:C22H23BrFN5O2Purity:98%Color and Shape:SolidMolecular weight:488.35EGFR-IN-61
CAS:EGFR-IN-61 inhibits EGFR kinase (IC50: 42 nM L858R/T790M, 137 nM L858R/T790M/C797S, 743 nM WT) and slows A549 & H1975 cell growth (IC50: 2.14 & 1.82 μM).Formula:C33H37ClN8O3Purity:98%Color and Shape:SolidMolecular weight:629.15EGFR-IN-85
CAS:EGFR-IN-85 (Compound 1), an EGFR inhibitor, exhibits potent activity with an IC50 of 0.19 μM against EGFRvⅢ phosphorylation and can suppress intratumoral EGFRFormula:C26H30N8O2Purity:98%Color and Shape:SolidMolecular weight:486.57EGFR-IN-30
CAS:EGFR-IN-30 is an EGFR inhibitor (IC50: 1-10 nM, <1 nM WT/mutants) with potential in cancer research.Formula:C28H33BrN7O2PColor and Shape:SolidMolecular weight:610.49Rocbrutinib
CAS:Rocbrutinib is a Bruton's tyrosine kinase (BTK) inhibitor that exhibits antineoplastic properties [1].Formula:C42H51N9O5Color and Shape:SolidMolecular weight:761.91HER2-IN-5
CAS:<p>HER2-IN-5 is an effective inhibitor of orally active HER-2.</p>Formula:C27H33N7O3Color and Shape:SolidMolecular weight:503.6EGFR-IN-29
CAS:EGFR-IN-29 is a potent EGFR inhibitor.Formula:C36H46BrN8O2PColor and Shape:SolidMolecular weight:733.68Lifirafenib
CAS:Lifirafenib (Beigene-283) is a potent inhibitor of RAF family kinases and EGFR in biochemical assays with IC50 of 23, 29 and 495 nM for the recombinantFormula:C25H17F3N4O3Purity:97.99% - 98%Color and Shape:SolidMolecular weight:478.42Labuxtinib
CAS:<p>Labutinib is a selective inhibitor of the c-kit tyrosine kinase [1].</p>Formula:C20H16FN5O2Purity:99.77%Color and Shape:SolidMolecular weight:377.37Nazartinib S-enantiomer
CAS:Nazartinib is an EGFR inhibitor. Nazartinib S-enantiomer is the less active S-enantiomer of Nazartinib.Formula:C26H31ClN6O2Purity:98%Color and Shape:SolidMolecular weight:495.02EGFR-IN-36
CAS:EGFR-IN-36 inhibits EGFR, HER2, & mutants with IC50s: 19.09 nM (EGFR WT), 120.01 nM (HER2 WT), 2.35 nM (HER2 mutant).Formula:C26H25ClN6O2Color and Shape:SolidMolecular weight:488.97EGFR-IN-1
CAS:<p>EGFR-IN-1: an oral, irreversible EGFR inhibitor targeting L858R/T790M mutations with high selectivity, showing potent antitumor effects.</p>Formula:C28H30N6O4Purity:98%Color and Shape:SolidMolecular weight:514.58HKI-357
CAS:<p>HKI-357 irreversibly inhibits EGFR/ERBB2 (IC50: 34/33 nM), blocks EGFR Y1068 autophosphorylation, and AKT/MAPK phosphorylation.</p>Formula:C31H29ClFN5O3Purity:99.91%Color and Shape:SolidMolecular weight:574.05EGFR/HER2-IN-13
CAS:EGFR/HER2-IN-13 (Compd 38) serves as an inhibitor targeting mutant EGFR/HER2s that show resistance to existing drugs. It is primarily utilized in cancer research.Formula:C27H36N8O3Molecular weight:520.63MS 154
CAS:MS 154 is a potent PROTAC® targeting mutant EGFR in lung cancer, sparing WT-EGFR; effective in mice, with DC50 of 11-25 nM.Formula:C46H54ClFN8O8Color and Shape:SolidMolecular weight:901.42Simotinib
CAS:Simotinib (AL-6802) is an EGFR tyrosine kinase inhibitor (IC50 : 19.9 nM) with antitumour activity for the study of non-small cell lung cancer.Formula:C25H26ClFN4O4Purity:99.7%Color and Shape:SolidMolecular weight:500.95PAT-505
CAS:PAT-505 is an autologous epidermal growth factor inhibitor.Formula:C23H18ClF2N3O2SPurity:98.84%Color and Shape:SolidMolecular weight:473.92EGFR-IN-32
CAS:EGFR-IN-32, a potent EGFR blocker, shows promise for EGFR-mutated illnesses. (Patent WO2021185297A1, compound 2)Formula:C31H34N6O3Color and Shape:SolidMolecular weight:538.64EGFR-IN-71
CAS:<p>EGFR-IN-71 is a potent inhibitor of epidermal growth factor receptor (EGFR) (IC50= 3.7 μM). EGFR-IN-71 has research value in chordoma.</p>Formula:C16H9ClIN3Color and Shape:SolidMolecular weight:405.62BEBT-109
CAS:BEBT-109 is a selective epidermal growth factor receptor (EGFR) inhibitor that shows anti-tumor activity in EGFR-mutant non-small cell lung cancer.Formula:C27H32N8O3Purity:97.26%Color and Shape:SolidMolecular weight:516.6BGB-102
CAS:<p>BGB-102 (JNJ-26483327) is a kinase inhibitor targeting FLT3 and YES1 and an antagonist targeting EGFR and VEGFR3.</p>Formula:C22H25BrN4O2Purity:99.02%Color and Shape:SolidMolecular weight:457.36EGFR-IN-74
EGFR-IN-74 is a potent inhibitor targeting EGFR, specifically effective against the L858R/T790M mutations, exhibiting an IC50 value of 138 nM.Formula:C32H28BrF3N6O4SColor and Shape:SolidMolecular weight:729.57EGFR mutant-IN-1
EGFR mutant-in-1, a 5-methylpyrimidopyridone, selectively inhibits EGFRL858R/T790M/C797S mutants with an IC50 of 27.5 nM, lessening EGFRWT impact.Formula:C34H39ClFN7O2Purity:98%Color and Shape:SolidMolecular weight:632.17BPIQ-I
CAS:BPIQ-I (PD 159121), an ATP-competitive EGFR tyrosine kinase inhibitor, exhibits potent anti-proliferative activity.Formula:C16H12BrN5Color and Shape:SolidMolecular weight:354.2PF-06459988
CAS:PF-06459988 is a novel, effective, orally active, irreversible, and selective epidermal growth factor receptor (EGFR) mutant inhibitor.Formula:C19H22ClN7O3Purity:98%Color and Shape:SolidMolecular weight:431.88EGFR-IN-33
CAS:EGFR-IN-33, a low-toxicity acrylamide, inhibits EGFR, aiding against cancer, especially NSCLC (from WO2021185348A1, comp. 13).Formula:C26H25ClN6O2Color and Shape:SolidMolecular weight:488.97(Z)-RG-13022
CAS:(Z)-RG-13022 is a tyrosine kinase (TK) inhibitor that preferentially inhibits the TK activity of the EGF receptor, restricting the EGF-stimulated growth of cultured cells. It demonstrates an IC50 of 11 μM for DNA synthesis in HN5 cells, showcasing thrice the potency of its isomer, (E)-RG-13022 (IC50 = 38 μM). This compound is applied in breast cancer cell research [1] [2].Formula:C16H14N2O2Color and Shape:SolidMolecular weight:266.29BGB-8035
CAS:<p>BGB-8035 is a BTK inhibitor with antitumor activity that inhibits BTK, TEC, and EGFR.BGB-8035 is used in the study of tumors and autoimmune diseases.</p>Formula:C24H31N5O4Purity:96.74%Color and Shape:SolidMolecular weight:453.53EGFR/ErbB-2 inhibitor-1
CAS:<p>EGFR/ErbB-2 inhibitor-1 is a selective ErbB2/HER2 inhibitor that effectively blocks ErbB2 and HER2 signaling.</p>Formula:C23H15ClFN3OS2Purity:98.93%Color and Shape:SolidMolecular weight:467.97EGFR-IN-87
CAS:EGFR-IN-87 is an EGFR tyrosine kinase inhibitor with potent inhibitory activity, exhibiting IC50 values of 3.1 nM, 1.3 nM, and 7.1 nM against EGFR_d746-750,Formula:C28H33N7O2Purity:98.64%Color and Shape:SolidMolecular weight:499.61EGFR-IN-1 hydrochloride
CAS:EGFR-IN-1 HCl targets L858R/T790M EGFR mutants over wild-type; IC50: 4 nM in H1975, 28 nM in mutant HCC827 cells.Formula:C28H31ClN6O4Purity:99.16%Color and Shape:SolidMolecular weight:551.04Sevabertinib
CAS:Sevabertinib (BAY 2927088) is an EGFR tyrosine kinase inhibitor, with anticancer activity, used in research on non-small cell lung cancer.Formula:C24H25ClN4O5Purity:99.81%Color and Shape:SolidMolecular weight:484.93EGFR-IN-8
CAS:<p>EGFR-IN-8, a dual inhibitor targeting both EGFR and c-Met, shows potential as a promising candidate for further development in treating EGFR TKI-resistant NSCLC</p>Formula:C32H23ClF3N7O4Purity:99.51%Color and Shape:SolidMolecular weight:662.02PROTAC Her3-binding moiety 2
CAS:PROTACHer3-binding moiety 2 is an inhibitor of Her3. It is applicable in the synthesis of PROTACHer3 Degrader-8.Formula:C25H25N7O2Color and Shape:SolidMolecular weight:455.51EGFR/HER2-IN-7
EGFR/HER2-IN-7: Potent, selective dual inhibitor for MCF-7 cancer; IC50: EGFR 0.18μM, HER2 0.146μM, DHFR 0.907μM.Formula:C19H21N3O2SColor and Shape:SolidMolecular weight:355.45EGFR-IN-48
<p>EGFR-IN-48: potent EGFR inhibitor, oral, IC50: 0.193-66.7 nM, blocks EGFR mutants & BaF3/PC-9 cell proliferation.</p>Color and Shape:SolidHER2-IN-7
CAS:HER2-IN-7 is a potent HER2 inhibitor with potential for researching ErbB-related diseases, especially cancer.Formula:C28H26F3N7O3Color and Shape:SolidMolecular weight:565.55EGFR-IN-126
CAS:EGFR-IN-126 (compound 9d) is an effective inhibitor of EGFR L858R/T790M/C797S, displaying an IC50 value of 0.005 μM. It exhibits antitumor activity both in vivo and in vitro.Formula:C28H28BrFN4O3Color and Shape:SolidMolecular weight:567.45EGFR Ligand-Linker Conjugates 1
CAS:EGFRLigand-Linker Conjugates 1 is a Target Protein Ligand-Linker Conjugate comprising an EGFR ligand and a PROTAC linker, designed to recruit the E3 ligase. It is used in the synthesis of PROTACEGFRdegrader 3.Formula:C37H47N9O3Color and Shape:SolidMolecular weight:665.83SORT1-IN-5
CAS:SORT1-IN-5 (compound 3) is a SORT1 inhibitor capable of crossing the blood-brain barrier. The MSOH salt form of SORT1-IN-5 exhibits a certain degree of oral bioavailability.Formula:C19H31NO6SColor and Shape:SolidMolecular weight:401.52Tyrphostin 63
CAS:Tyrphostin 63 (compound 13) is an epidermal growth factor receptor (EGFR) inhibitor, with an IC50 of 375 μM and a Ki of 123 μM.Formula:C10H8N2OColor and Shape:SolidMolecular weight:172.183SST0116CL1
CAS:<p>SST0116CL1 is an HSP90 inhibitor (IC50: 0.21 μM) that targets the ATP-binding pocket of Hsp90, disrupting its chaperone function and leading to the degradation of client proteins (EGFR, CDK4, and AKT). It induces the degradation of Her2 in BT-474 cells (IC50: 0.2 μM) and exhibits antiproliferative activity, inhibiting tumor growth.</p>Formula:C22H31ClN4O6Color and Shape:SolidMolecular weight:482.96ES-072
CAS:<p>ES-072, a selective inhibitor targeting the EGFR mutant (EGFR-T790M), is administered orally. By hindering EGFR-T790M activity, it activates GSK3α, which subsequently leads to the phosphorylation of PD-L1 at Ser279 and Ser283. This phosphorylation facilitates the recruitment of the E3 ubiquitin ligase ARIH1, resulting in the ubiquitination and proteasomal degradation of PD-L1. Such a process not only curtails the growth of cancer cells but also amplifies the anti-tumor immune response by diminishing PD-L1 levels. ES-072 has shown efficacy in impeding the proliferation of non-small cell lung cancer (NSCLC) cells.</p>Formula:C25H27F3N8O2Color and Shape:SolidMolecular weight:528.53BPI-15086
CAS:BPI-15086 is an orally active, effective, irreversible inhibitor selective for mutations, targeting both EGFR and the T790M resistance mutation tyrosine kinase. It can be utilized in the study of non-small cell lung cancer.Formula:C29H33ClN8O4Color and Shape:SolidMolecular weight:593.08EGFR-IN-18
EGFR-IN-18 strongly inhibits L858R/T790M/C797S mutant EGFR (4.9 nM) and also targets wild-type EGFR (47 nM).Formula:C33H28N6O3SColor and Shape:SolidMolecular weight:588.68EGFR-IN-38
CAS:EGFR-IN-38: low-toxic acrylamide-derived EGFR inhibitor, targets NSCLC, patented for research on EGFR mutation-related diseases.Formula:C25H24ClN7O2Color and Shape:SolidMolecular weight:489.96Neptinib
CAS:<p>Neptinib (NEP010), a derivative of Afatinib, exhibits enhanced antitumor properties and improved pharmacokinetics when administered orally. It demonstrates a notable suppression of tumor expansion in mouse models of non-small cell lung cancer harboring various EGFR mutations. Furthermore, Neptinib effectively inhibits the EGFR kinase family, exhibiting IC 50 values of 0.24 nM for EGFR wt, 7.25 nM for EGFR L858R/T790M, 0.46 nM for EGFR L858R, and 1.79 nM for EGFR T790M.</p>Formula:C22H23ClFN5O2Color and Shape:SolidMolecular weight:443.90Tarloxotinib bromide
CAS:Tarloxotinib bromide (TH-4000) is an irreversible inhibitor of EGFR/HER2.Formula:C24H24Br2ClN9O3Purity:99.52%Color and Shape:SolidMolecular weight:681.77EGFR-IN-139
CAS:EGFR-IN-139 (compound PD 18) is an EGFR inhibitor with IC50 values of 12.88 nM (wild type), 10.84 nM (L858R/T790M), and 42.68 nM (L858R/T790M/C797S). It demonstrates significant anticancer activity against the A549 and H1975 cancer cell lines, which express high levels of EGFR. EGFR-IN-139 exhibits strong selectivity for cancer cells and can be utilized in research on non-small cell lung cancer (NSCLC).Formula:C27H25ClN2O4Color and Shape:SolidMolecular weight:476.951EGFR-IN-17
EGFR-IN-17: potent, selective EGFR inhibitor, IC50 of 0.2 nM, overcomes C797S drug resistance.Formula:C27H31ClN7O3PColor and Shape:SolidMolecular weight:568.01EGFR-IN-159
CAS:<p>EGFR-IN-159 (compound 12) is a dihydropyrimidine and a potent EGFR inhibitor with an IC50 of 29.00 nM. It exhibits dose-dependent inhibition of EGFR and HER2. The compound shows cytotoxicity against MCF-7 breast cancer cells and Vero cells with IC50 values of 16.07 μg/mL and 35.98 μg/mL, respectively. EGFR-IN-159 does not cross the blood-brain barrier (BBB) and demonstrates significant anticancer activity.</p>Formula:C21H23N3O5Color and Shape:SolidMolecular weight:397.424EGFR-IN-24
EGFR-IN-24 is a potent inhibitor of EGFR and inhibits EGFR (del19/T790M/C797S) and EGFR (L858R/T790M/C797S).Formula:C30H35FN6O3Color and Shape:SolidMolecular weight:546.64Andamertinib
CAS:Andamertinib is an EGFR inhibitor with antitumor activity.Formula:C31H36N8O3Color and Shape:SolidMolecular weight:568.669EGFR/BRAF-IN-1
EGFR/BRAF-IN-1 inhibits EGFR/BRAF (BRAFV600E IC50: 45 nM, GI50: 35 nM) and has antioxidant properties.Formula:C26H28ClN3O4Color and Shape:SolidMolecular weight:481.97EGFR-IN-23
CAS:EGFR-IN-23, identified as compound 8 in WO2021244502A1, is a potent EGFR tyrosine kinase inhibitor (TKI) demonstrating an inhibitory concentration (IC50) of 8.Formula:C36H44BrN10O3PColor and Shape:SolidMolecular weight:775.68HER2-IN-9
HER2-IN-9, an oral HER2 inhibitor (IC50: 0.03 μM), hinders growth and spread of HER2+ breast cancer.Formula:C19H14BrF3N2OColor and Shape:SolidMolecular weight:423.23BML-265
CAS:BML-265 is a potent inhibitor of EGFR tyrosine kinase (EGFR tyrosine kinase). It disrupts Golgi apparatus integrity in human cells and hinders the transport of secretory proteins across various substances. In contrast, BML-265 does not affect the integrity and transport of the Golgi apparatus in rodent cells.Formula:C18H15N3O2Color and Shape:SolidMolecular weight:305.331EGFR/HER2/DHFR-IN-1
Potent EGFR/HER2/DHFR inhibitor for MCF-7 breast cancer; IC50: 0.153/0.108/0.291 μM; arrests G1/S phase, triggers apoptosis.Formula:C14H11BrN4O2SColor and Shape:SolidMolecular weight:379.23HER2-IN-8
CAS:HER2-IN-8 is an inhibitor of HER-2 that can be used in the study of cancer and inflammation-related diseases.Formula:C26H25F2N9O3Color and Shape:SolidMolecular weight:549.53EGFR/HER2-IN-8
EGFR/HER2-IN-8 inhibits EGFR, HER2, DHFR (IC50: 0.45, 0.244, 5.669 μM); useful in cancer research, safe and selective.Formula:C16H16N4O2SColor and Shape:SolidMolecular weight:328.39HER2-IN-21
CAS:<p>HER2-IN-21 (compound 657994) is an inhibitor of the human epidermal growth factor receptor 2 (HER2) with an IC50 value of 3.85 μM.</p>Formula:C20H18N4O3SColor and Shape:SolidMolecular weight:394.447NSC381467
CAS:NSC381467: Potent, oral EGFR-TK inhibitor with strong antiproliferative effects, promising for cancer research.Formula:C20H16O7Color and Shape:SolidMolecular weight:368.34EGFR ligand-14
CAS:EGFRligand-14 serves as an EGFR ligand and is utilized in the synthesis of SJF-1521.Formula:C27H19ClFN3OColor and Shape:SolidMolecular weight:455.91EGFR-IN-160
CAS:EGFR-IN-160 is an EGFR inhibitor with IC50 values of 1.62, 0.49, and 0.98 μM for EGFRWT, EGFRT790M, and EGFRL858R/T790M/C797S, respectively. It can induce cell cycle arrest at the G2/M and S phases and apoptosis (Apoptosis) in NCI-H522 cells, demonstrating anticancer properties. Additionally, EGFR-IN-160 exhibits antioxidant activity against DPPH (IC50: 12.11 µM) and H2O2 (IC50: 8.89 µM).Formula:C15H12N2O4Color and Shape:SolidMolecular weight:284.27Sacibertinib
CAS:Sacibertinib inhibits Trk, targeting EGFR-TK (EC50 110 nM) & HER2 (EC50 244 nM), with anticancer properties.Formula:C32H31ClN6O4Color and Shape:SolidMolecular weight:599.08EGFR-IN-147
CAS:EGFR-IN-147 (compound ID-5841161) is a potent EGFR inhibitor, demonstrating a 14% inhibition rate at a concentration of 1μM. It holds promise for cancer research applications.Formula:C13H13N5OColor and Shape:SolidMolecular weight:255.275JBJ-02-112-05
CAS:JBJ-02-112-05 is a potent, mutant-selective, allosteric and orally active inhibitor of EGFR with an IC 50 of 15 nM for EGFR L858R/T790M [1].Formula:C27H20N4O2SPurity:98%Color and Shape:SolidMolecular weight:464.54EGFR-IN-34
EGFR-IN-34 is a low-toxicity, acrylamide derivative antitumor agent that is a potent inhibitor of EGFR.Formula:C26H27ClN6O2Color and Shape:SolidMolecular weight:490.98JBJ-09-063
CAS:JBJ-09-063: EGFR inhibitor, IC50s 0.147-0.396 nM for various mutants; hinders EGFR/Akt/ERK1/2 phosphorylation; targets TKI-sensitive/resistant lung cancer.Formula:C31H29FN4O3SColor and Shape:SolidMolecular weight:556.65EG31
CAS:EG31 is an EGFR inhibitor that effectively suppresses the proliferation of triple-negative breast cancer (TNBC) cells by inhibiting the EGFR signaling pathway. It demonstrates a GI50 value of 498.90 nM for MDA-MB-231 cells and 740.73 nM for Hs578T cells, while also inducing apoptosis. Additionally, EG31 retains its antiproliferative activity against 5-fluorouracil (5-FU) resistant TNBC cells, with a GI50 of 519.5 nM. EG31 is applicable in research on TNBC resistance.Formula:C30H13Br2N3O6Color and Shape:SolidMolecular weight:671.25HER2-IN-6
CAS:HER2-IN-6, a potent HER2 inhibitor, may target wild/mutant EGFR and HER2-mediated tumors. (Patent WO2021164697A1, compound 11)Formula:C26H32N8O3Color and Shape:SolidMolecular weight:504.58EGFR-IN-58
EGFR-IN-58 is a potent, selective, ATP-competitive inhibitor of EGFR. EGFR-IN-58 exhibits significant cytotoxicity against melanoma, colon and blood cancers.Formula:C31H30FN7OColor and Shape:SolidMolecular weight:535.61EGFR/HER2-IN-4
EGFR/HER2-IN-4: oral, irreversible dual EGFR inhibitor (IC50: 0.6 nM), targets L858R/T790M mutations, potent anti-lung cancer effects in vivo.Color and Shape:SolidTesevatinib tosylate
CAS:Tesevatinib tosylate (XL-647 tosylate) is an orally administered epidermal growth factor receptor (EGFR) inhibitor that can cross the blood-brain barrier. It significantly reduces cell viability with IC50 values of 11 nM and 102 nM in GBM12 and GBM6, respectively. Additionally, Tesevatinib tosylate inhibits HER2 (IC50=16.1 nM), VEGFR2 (IC50=1.5 nM), and Src (IC50=10.3 nM), demonstrating antitumor activity by inhibiting tumor proliferation.Formula:C31H33Cl2FN4O5SColor and Shape:SolidMolecular weight:663.59EGFR-IN-132
CAS:EGFR-IN-132 (Compound 23) is an EGFR inhibitor effective against various EGFR mutations including the wild-type, L858R/T790M, d19/T790M, L858R/T790M/C797S, and d19/T790M/C797S with IC50 values of 1.6, 0.025, 0.019, 0.022, and 0.029 nM, respectively. This compound demonstrates favorable pharmacokinetics with high oral bioavailability.Formula:C27H31N7O3Color and Shape:SolidMolecular weight:501.58HER2-IN-12
HER2-IN-12 is an HER2 inhibitor with an IC50 value of 121 nM and can be used to study cancers such as breast cancer.Formula:C17H18BrN5O2SColor and Shape:SolidMolecular weight:436.33D-69491 hydrochloride
CAS:D-69491 hydrochloride is an inhibitor of HER-2 tyrosine kinase activity, blocking the phosphorylation of HER-2 and inhibiting the proliferation of SKOV-3 cells. It exhibits antitumor activity.Formula:C25H26Cl2FN7O3Color and Shape:SolidMolecular weight:562.42EGFR-IN-130
EGFR-IN-130 (compound 14b) is an EGFR inhibitor and an inducer of apoptosis (apoptoosis). It effectively kills HeLa cancer cells by inducing apoptosis.Formula:C27H25N3O6SColor and Shape:SolidMolecular weight:519.57EGFR-IN-135
EGFR-IN-135 (compound 3d) is an EGFR inhibitor with an IC50 value of 0.086 µM. It inhibits cell growth and arrests the cell cycle in the S phase in breast cancer cell lines.Formula:C12H14N4OS2Color and Shape:SolidMolecular weight:294.4EGFR-IN-125
CAS:<p>EGFR-IN-125 (example 37) is a potent EGFR inhibitor with IC50 values of <0.3 nM for EGFR(d746-750/T790M/C797S), 0.52 nM for EGFR(L858R/T790M/C797S), 0.5 nM for EGFR(d746-750/C797S), 0.69 nM for EGFR(L858R/C797S), and 0.92 nM for EGFR (wild type).</p>Formula:C30H26N8OColor and Shape:SolidMolecular weight:514.58Si306
CAS:Si306, an Src inhibitor, exhibits antitumor activity by reducing the phosphorylation of focal adhesion kinase (FAK) and the expression of epidermal growth factor receptor (EGFR), thereby inhibiting the invasion of human glioblastoma (GBM).Formula:C25H26BrClN6OSColor and Shape:SolidMolecular weight:573.94EGFR-IN-149
CAS:EGFR-IN-149 (Compound 3-OH) is an EGFR inhibitor with an IC50 value of 0.42 nM.Formula:C16H15N3OSColor and Shape:SolidMolecular weight:297.375EGFR/HER2-IN-5
<p>EGFR/HER2-IN-5: Irreversible, oral dual EGFR inhibitor, IC50 0.6 nM, targets L858R/T790M mutations, anti-tumor in vivo for lung cancer study.</p>Color and Shape:SolidEGFR-IN-35
CAS:EGFR-IN-35, an acrylamide-based EGFR inhibitor, shows promise for EGFR mutation-related cancers like NSCLC.Formula:C25H24ClN7O2Color and Shape:SolidMolecular weight:489.96LSD1/EGFR-IN-1
CAS:<p>LSD1/EGFR-IN-1 (compound L-1) is an effective inhibitor of LSD1, EGFRT790M/L858R, and EGFRL858R/T790M/C797S, with IC50 values of 6.24, 2.06, and 5.01 μM, respectively. This compound plays a significant role in cancer research.</p>Formula:C21H20ClN3O4Color and Shape:SolidMolecular weight:413.854EGFR-IN-7
CAS:<p>EGFR-IN-7 (TQB3804) is a selective and potent EGFR kinase inhibitor.</p>Formula:C32H41BrN9O2PPurity:95.32% - 99.64%Color and Shape:SolidMolecular weight:694.6TLC9995-0188
CAS:Tyrosine-protein kinase ABL, IC50: 1500 nMFormula:C16H15N5Color and Shape:Yellow SolidMolecular weight:277.331Nimotuzumab (powder)
CAS:<p>Nimotuzumab (powder) is a humanized IgG1 monoclonal antibody that specifically targets the epidermal growth factor receptor (EGFR), possessing a dissociation constant (KD) of 0.21 nM. It blocks the binding to its ligand by targeting the extracellular domain of EGFR. Nimotuzumab exhibits strong antitumor activity by inducing both antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), exerting cytolytic effects on target tumors.</p>Color and Shape:LiquidImbotolimod
Imbotolimod, a humanized monoclonal antibody of the immunoglobulin G1-kappa class, exhibits both anti-ERBB2 and antineoplastic activities.Color and Shape:Odour LiquidHMBD-001
<p>HMBD-001 is a humanized IgG1 monoclonal antibody inhibitor that targets HER3. By inhibiting the dimerization of HER3, HMBD-001 suppresses the growth and proliferation of tumor cells. It holds potential for research in cancer treatments, specifically for pancreatic cancer and non-small cell lung cancer.</p>Color and Shape:Odour LiquidOlmutinib
CAS:Olmutinib (BI1482694) is a Novel Epidermal Growth Factor Receptor Tyrosine Kinase InhibitorFormula:C26H26N6O2SPurity:99.14%Color and Shape:SolidMolecular weight:486.59Duligotuzumab
CAS:<p>Duligotuzumab (MEHD-7945A) is a bispecific humanised IgG-κ monoclonal antibody targeting HER3 and EGFR, solid tumours, head and neck cancer,colorectal cancer.</p>Purity:95%Color and Shape:LiquidRef: TM-T80604
Discontinued productEGFR-IN-82
CAS:<p>EGFR-IN-82 (Compound 8a) is a potent, orally active inhibitor of EGFR, exhibiting IC50 values of 0.09 nM for EGFR L858R/T790M/C797S and 0.06 nM for EGFR Del19/</p>Formula:C32H41BrN9O2PPurity:98%Color and Shape:SolidMolecular weight:694.6YK-029A
CAS:<p>YK-029A, an orally active EGFR mutant inhibitor, targets both EGFR T790M and EGFRex20ins mutations.</p>Formula:C27H32N8O2Purity:98%Color and Shape:SolidMolecular weight:500.6EGFR-IN-122
CAS:<p>EGFR-IN-122 (compound Yfq07) serves as a potent inhibitor of EGFR. It effectively inhibits the proliferation of PC-9GR and HCC827GR cells.</p>Formula:C19H20N4O3Color and Shape:SolidMolecular weight:352.39Ref: TM-T200157
Discontinued productEGFR-IN-123
CAS:<p>EGFR-IN-123 (compound D06) is an effective EGFR inhibitor. It exhibits inhibitory activity against several cell lines including PC-9G, A549, A431, and HCT116, with IC50 values of 0.74, 1.36, 1.20, and 2.53 μM respectively.</p>Formula:C24H27F3N6OColor and Shape:SolidMolecular weight:472.51Ref: TM-T200485
Discontinued product
